{"id":"W2155477677","doi":"10.1016/j.breast.2015.04.006","title":"One step forward, two steps back: The story of everolimus in advanced breast cancer","year":2015,"lang":"en","type":"article","venue":"The Breast","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba; University of Toronto; CancerCare Manitoba","funders":"","keywords":"Medicine; Everolimus; Bevacizumab; Breast cancer; Drug; Anticancer drug; Cancer; Cancer drugs; Clinical trial; Intensive care medicine; Oncology; Internal medicine; Pharmacology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006613366,0.0007254847,0.001404384,0.001166627,0.002475525,0.004954623,0.001201831,0.008156264,0.00261807],"category_scores_gemma":[0.01209847,0.0003881,0.001075073,0.001084391,0.006811334,0.01286956,0.003257713,0.02824213,0.001561125],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002859036,"about_ca_system_score_gemma":0.001947435,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002626383,"about_ca_topic_score_gemma":0.007320664,"domain_scores_codex":[0.9977863,0.001184785,0.0001225693,0.0001846667,0.0005300266,0.0001917155],"domain_scores_gemma":[0.9926231,0.005434775,0.0002766834,0.0001671544,0.0006879275,0.000810399],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004504084,0.0001060294,0.0006849836,0.001497216,0.0000939894,0.001589724,0.001904751,0.0004501793,0.0008599915,0.09680239,0.7110314,0.184529],"study_design_scores_gemma":[0.00005598806,0.0002158817,0.000593392,0.001236479,0.00005483284,0.002336082,0.001760602,0.0002576878,0.0002574216,0.05576313,0.9374039,0.00006468743],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.0009557809,0.3888265,0.0006105964,0.5830697,0.02088726,0.000008267209,0.0000544687,0.00002743297,0.005560082],"genre_scores_gemma":[0.02122062,0.5462169,0.001529317,0.3331937,0.08817015,0.00003528767,0.00006302453,0.00008629158,0.009484658],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.008156264,"threshold_uncertainty_score":0.03497523,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02577296856479245,"score_gpt":0.2992484553007128,"score_spread":0.2734754867359204,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}